Table 2.
Clinicopathological variables and the expression of miR-1908-3p in the serum of breast cancer
| Variable | Number | Mean of miR-1908-3p expression | p value |
|---|---|---|---|
| Age | < 0.001 | ||
| ≤ 40 | 27 (45%) | 30.41 | |
| > 40 | 33 (55%) | 5.18 | |
| Metastasis | 0.723 | ||
| Negative | 25 (42%) | 15.42 | |
| Positive | 35 (58%) | 17.33 | |
| Grade | 0.086 | ||
| 1 | 11 (18%) | 15.77 | |
| 2 | 20 (33%) | 9.01 | |
| 3 | 29 (49%) | 22.00 | |
| TNM | 0.072 | ||
| I/II | 46 (77%) | 16.00 | |
| III/IV | 14 (23%) | 18.26 | |
| Tumor size | 0.721 | ||
| ≤ 2 | 22 (37%) | 15.46 | |
| > 2,≤5 | 35 (58%) | 16.42 | |
| > 5 | 3 (5%) | 25.73 | |
| ER statue | 0.65 | ||
| Negative | 19 (32%) | 18.29 | |
| Positive | 41 (68%) | 15.72 | |
| PR statue | 0.418 | ||
| Negative | 22 (37%) | 19.36 | |
| Positive | 38 (63%) | 14.89 | |
| HER-2 | 0.489 | ||
| Negative | 52 (87%) | 15.81 | |
| Positive | 8 (13%) | 21.22 | |
| Molecular Subtype | 0.786 | ||
| luminal | 41 (68%) | 15.72 | |
| her-2+ | 5 (8%) | 14.86 | |
| triple-negative | 14 (24%) | 19.79 |
Abbreviations: ER estrogen receptor, PR progesterone receptor, HER-2 human epidermal growth factor receptor 2